LAG3 and neoplasm: While the exact mechanisms of LAG-3 remain controversial, this immune checkpoint has gained prominence with the development of relatlimab (anti-LAG-3 antibody) which has recently been shown to improve anti-tumor activity in combination with nivolumab (19).